Capricor Therapeutics Inc. (CAPR) 7.25 $CAPR
Healthways (HWAY) Lags Q1 Earnings, Revenue Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 9:40AM CDT
Healthways Inc. (HWAY) reported first-quarter 2015 adjusted loss of 5 cents per share, wider than the Zacks Consensus Estimate of a loss of 3 cents
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), HWAY: 17.61 (-1.89)
Merit Medical (MMSI) Q1 Earnings, Revenues Beat; Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 9:15AM CDT
Merit Medical Systems, Inc. (MMSI) reported adjusted earnings per share (EPS) of 18 cents, beating the Zacks Consensus Estimate of 15 cents
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), MMSI: 20.58 (+1.34)
Capricor's CAP-1002 Gets Orphan Drug Status in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 4:53PM CDT
Capricor's (CAPR) CAP-1002 has been granted orphan drug status in the U.S. for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.
CRMD: 8.61 (-0.22), BIIB: 401.71 (-28.57), CAPR: 7.25 (-0.75), AVEO: 1.92 (-0.08)
Accuray's (ARAY) InCise MLC Reaches International Markets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 4:49PM CDT
Accuray Incorporated (ARAY) recently announced the availability of its InCise Multileaf Collimator (MLC) for the CyberKnife M6 System in international markets, where it has already been approved for commercialization.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), ARAY: 9.11 (-0.11)
Capricor cell therapy candidate an Orphan Drug for Duchenne muscular dystrophy
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:56AM CDT
ROSG: 3.72 (+0.06), CAPR: 7.25 (-0.75), BMRN: 120.28 (-2.67), RNA: 18.65 (unch), PFE: 35.27 (-0.09), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88), SMMT: 10.30 (-0.20)
St. Jude Medical (STJ) Beats on Q1 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:52AM CDT
St. Jude Medical Inc (STJ) reported adjusted earnings per share (EPS) of 93 cents in the first quarter of 2015, outpacing the Zacks Consensus Estimate by a couple of cents.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), STJ: 73.47 (-0.54)
Stryker Q1 Earnings Beat, Revenues in Line; Both Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:10AM CDT
Stryker Corporation (SYK) reported modest first-quarter 2015 earning results. Adjusted earnings per share (EPS) of $1.11 beat the Zacks Consensus Estimate by a couple of cents while net sales of $2.38 billion were almost in line with the mark
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), SYK: 96.90 (-0.28)
Capricor Granted FDA Orphan Drug Designation for Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy
GlobeNewswire - Wed Apr 22, 7:15AM CDT
Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its cell therapeutic product candidate, CAP-1002, for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
CAPR: 7.25 (-0.75)
St. Jude Medical to Boost Chronic Pain Management Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:25PM CDT
St. Jude Medical, Inc. (STJ) recently announced its plans to acquire Spinal Modulation, Inc., developer of the Axium Neurostimulator System.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), STJ: 73.47 (-0.54)
Is Patterson (PDCO) Mulling Medical Segment Divesture? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 4:58PM CDT
Reportedly, Patterson Companies, Inc. (PDCO) is contemplating divestiture of its rehabilitation supply business, known as Patterson Medical. According to Reuters, the transaction could be valued between $500 million and $600 million.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), PDCO: 48.19 (+0.70), BAC: 15.64 (-0.05)
Thoratec's HeartMate II Scores High in ENDURANCE Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 4:35PM CDT
Thoratec Corp. (THOR) recently presented positive data for its HeartMate II heart pump device from the ENDURANCE destination therapy trial.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), THOR: 42.31 (-0.46)
athenahealth to Boost Health Management at Trinity Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 3:13PM CDT
athenahealth, Inc. (ATHN) recently announced that it has been selected by Trinity Health to drive better clinical integration and people-centered care its multi-state ambulatory network.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), ATHN: 125.30 (+3.30)
Quality Systems Unveils Health Care Platform, Buys Gennius - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 1:10PM CDT
Mirth, LLC, a wholly owned subsidiary of Quality Systems, Inc. (QSII), recently launched a new population health management suite ??? Mirth Care Enterprise. Quality Systems also announced the acquisition of healthcare data analytics provider, Gennius.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), QSII: 15.80 (-0.04)
Walgreens Boots to Close 200 Drugstores in US, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 10, 12:00PM CDT
Walgreens Boots (WBA) expects to open roughly the same number of stores, going forward, but strictly in locations with higher profit potential.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), WBA: 85.98 (-0.71), LMAT: 8.60 (+0.03)
Ecolab's 3D TRASAR CIP Program Named Product of the Year - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 12:50PM CDT
Ecolab Inc. (ECL), recently announced that its 3D TRASAR CIP (Clean-in-Place) technology has received the 'Product of the Year' award from the Environmental Leader magazine.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), ECL: 115.59 (-0.26)
Walgreens Boots (WBA) Tops Q2 Earnings, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 10:08AM CDT
Walgreens Boots (WBA) reported a mixed second-quarter fiscal 2015 with earnings comfortably beating the Zacks Consensus Estimate, but the top line missing the mark
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), WBA: 85.98 (-0.71), LMAT: 8.60 (+0.03)
Cerner Teams Up to Start 'Aging in Place' Community Program - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 1:30PM CDT
Cerner Corp. (CERN) has united with North Kansas City Hospital, K2 Consulting Solutions, LifeWise Renovations and Northland Shepherd's Center to create a joint, public-private community program called 'Aging in Place'.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), CERN: 73.32 (+0.27)
Medtronic Up on Positive EverFlex Peripheral Stent Trial Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 12:50PM CDT
Medtronic's EverFlex helps in expanding and reopening the narrowed regions of the SFA and proximal popliteal arteries to facilitate normal blood circulation in the legs.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), MDT: 77.61 (-0.89), LMAT: 8.60 (+0.03)
Capricor Completes Enrollment of Initial Phase of DYNAMIC Clinical Trial of Cardiosphere-Derived Cell Therapy for Treatment of Advanced Heart Failure
GlobeNewswire - Wed Apr 08, 7:00AM CDT
Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has completed enrollment of the initial phase of its DYNAMIC clinical trial for the treatment of advanced heart failure. DYNAMIC is a trial of CAP-1002, Capricor's allogeneic, cardiosphere-derived cell (CDC) therapy in clinical development for the treatment of advanced heart failure, including patients who were Class III or ambulatory Class IV with ejection fractions of 35% or below.
CAPR: 7.25 (-0.75)
Cerner Enjoys Industry Recognitions, Wins EHNAC Accredition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 12:40PM CDT
Cerner Corp. (CERN) has added yet another feather to its cap. The company recently achieved full accreditation with the Direct Trusted Agent Accreditation Program (DTAAP).
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), CERN: 73.32 (+0.27)
Healthways (HWAY) Lags Q1 Earnings, Revenue Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 9:40AM CDT
Healthways Inc. (HWAY) reported first-quarter 2015 adjusted loss of 5 cents per share, wider than the Zacks Consensus Estimate of a loss of 3 cents
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), HWAY: 17.61 (-1.89)
Merit Medical (MMSI) Q1 Earnings, Revenues Beat; Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 9:15AM CDT
Merit Medical Systems, Inc. (MMSI) reported adjusted earnings per share (EPS) of 18 cents, beating the Zacks Consensus Estimate of 15 cents
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), MMSI: 20.58 (+1.34)
Capricor's CAP-1002 Gets Orphan Drug Status in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 4:53PM CDT
Capricor's (CAPR) CAP-1002 has been granted orphan drug status in the U.S. for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.
CRMD: 8.61 (-0.22), BIIB: 401.71 (-28.57), CAPR: 7.25 (-0.75), AVEO: 1.92 (-0.08)
Accuray's (ARAY) InCise MLC Reaches International Markets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 4:49PM CDT
Accuray Incorporated (ARAY) recently announced the availability of its InCise Multileaf Collimator (MLC) for the CyberKnife M6 System in international markets, where it has already been approved for commercialization.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), ARAY: 9.11 (-0.11)
Capricor cell therapy candidate an Orphan Drug for Duchenne muscular dystrophy
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:56AM CDT
ROSG: 3.72 (+0.06), CAPR: 7.25 (-0.75), BMRN: 120.28 (-2.67), RNA: 18.65 (unch), PFE: 35.27 (-0.09), SRPT: 13.42 (-0.24), PTCT: 70.48 (-0.88), SMMT: 10.30 (-0.20)
St. Jude Medical (STJ) Beats on Q1 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:52AM CDT
St. Jude Medical Inc (STJ) reported adjusted earnings per share (EPS) of 93 cents in the first quarter of 2015, outpacing the Zacks Consensus Estimate by a couple of cents.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), STJ: 73.47 (-0.54)
Stryker Q1 Earnings Beat, Revenues in Line; Both Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:10AM CDT
Stryker Corporation (SYK) reported modest first-quarter 2015 earning results. Adjusted earnings per share (EPS) of $1.11 beat the Zacks Consensus Estimate by a couple of cents while net sales of $2.38 billion were almost in line with the mark
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), SYK: 96.90 (-0.28)
Capricor Granted FDA Orphan Drug Designation for Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy
GlobeNewswire - Wed Apr 22, 7:15AM CDT
Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its cell therapeutic product candidate, CAP-1002, for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
CAPR: 7.25 (-0.75)
St. Jude Medical to Boost Chronic Pain Management Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:25PM CDT
St. Jude Medical, Inc. (STJ) recently announced its plans to acquire Spinal Modulation, Inc., developer of the Axium Neurostimulator System.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), STJ: 73.47 (-0.54)
Is Patterson (PDCO) Mulling Medical Segment Divesture? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 4:58PM CDT
Reportedly, Patterson Companies, Inc. (PDCO) is contemplating divestiture of its rehabilitation supply business, known as Patterson Medical. According to Reuters, the transaction could be valued between $500 million and $600 million.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), PDCO: 48.19 (+0.70), BAC: 15.64 (-0.05)
Thoratec's HeartMate II Scores High in ENDURANCE Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 4:35PM CDT
Thoratec Corp. (THOR) recently presented positive data for its HeartMate II heart pump device from the ENDURANCE destination therapy trial.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), THOR: 42.31 (-0.46)
athenahealth to Boost Health Management at Trinity Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 3:13PM CDT
athenahealth, Inc. (ATHN) recently announced that it has been selected by Trinity Health to drive better clinical integration and people-centered care its multi-state ambulatory network.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), ATHN: 125.30 (+3.30)
Quality Systems Unveils Health Care Platform, Buys Gennius - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 1:10PM CDT
Mirth, LLC, a wholly owned subsidiary of Quality Systems, Inc. (QSII), recently launched a new population health management suite ??? Mirth Care Enterprise. Quality Systems also announced the acquisition of healthcare data analytics provider, Gennius.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), QSII: 15.80 (-0.04)
Walgreens Boots to Close 200 Drugstores in US, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 10, 12:00PM CDT
Walgreens Boots (WBA) expects to open roughly the same number of stores, going forward, but strictly in locations with higher profit potential.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), WBA: 85.98 (-0.71), LMAT: 8.60 (+0.03)
Ecolab's 3D TRASAR CIP Program Named Product of the Year - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 12:50PM CDT
Ecolab Inc. (ECL), recently announced that its 3D TRASAR CIP (Clean-in-Place) technology has received the 'Product of the Year' award from the Environmental Leader magazine.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), ECL: 115.59 (-0.26)
Walgreens Boots (WBA) Tops Q2 Earnings, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 10:08AM CDT
Walgreens Boots (WBA) reported a mixed second-quarter fiscal 2015 with earnings comfortably beating the Zacks Consensus Estimate, but the top line missing the mark
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), WBA: 85.98 (-0.71), LMAT: 8.60 (+0.03)
Cerner Teams Up to Start 'Aging in Place' Community Program - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 1:30PM CDT
Cerner Corp. (CERN) has united with North Kansas City Hospital, K2 Consulting Solutions, LifeWise Renovations and Northland Shepherd's Center to create a joint, public-private community program called 'Aging in Place'.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), CERN: 73.32 (+0.27)
Medtronic Up on Positive EverFlex Peripheral Stent Trial Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 12:50PM CDT
Medtronic's EverFlex helps in expanding and reopening the narrowed regions of the SFA and proximal popliteal arteries to facilitate normal blood circulation in the legs.
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), MDT: 77.61 (-0.89), LMAT: 8.60 (+0.03)
Capricor Completes Enrollment of Initial Phase of DYNAMIC Clinical Trial of Cardiosphere-Derived Cell Therapy for Treatment of Advanced Heart Failure
GlobeNewswire - Wed Apr 08, 7:00AM CDT
Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has completed enrollment of the initial phase of its DYNAMIC clinical trial for the treatment of advanced heart failure. DYNAMIC is a trial of CAP-1002, Capricor's allogeneic, cardiosphere-derived cell (CDC) therapy in clinical development for the treatment of advanced heart failure, including patients who were Class III or ambulatory Class IV with ejection fractions of 35% or below.
CAPR: 7.25 (-0.75)
Cerner Enjoys Industry Recognitions, Wins EHNAC Accredition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 12:40PM CDT
Cerner Corp. (CERN) has added yet another feather to its cap. The company recently achieved full accreditation with the Direct Trusted Agent Accreditation Program (DTAAP).
CAPR: 7.25 (-0.75), SRDX: 26.53 (+0.03), LMAT: 8.60 (+0.03), CERN: 73.32 (+0.27)
